prostaglandin E receptor 2Genealiases: COX-2 · EP2
Q-omics provides the consensus-scored PTGER2 profile across patient tissues and cancer cell-line models. PTGER2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PTGER2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PTGER2 RNA expression shows 21,764 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KICH, and LSCC as cancer lineages where PTGER2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTGER2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTGER2 survival associations across molecular data types. PTGER2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTGER2 RNA expression–survival associations across cancer types. High PTGER2 expression shows unfavorable associations in KIRC, LUSC, LGG and UVM, but favorable associations in SKCM and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PTGER2 RNA expression.
This table summarizes PTGER2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PTGER2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTGER2 shows lower tumor expression in KICH, LUSC, UCEC, BRCA, BLCA and THCA. The KICH box plot shows higher PTGER2 RNA expression in normal versus tumor tissue (log2 FC = −2.564, t-test p < 0.001).
This table shows molecular features associated with PTGER2 in patient tissues and cancer cell lines. In patient samples, PTGER2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTGER2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
